AbbVie cuts 2026 EPS guidance after $744 million first-quarter IPR&D charge
AbbVie said its first-quarter 2026 results will include $744 million in pre-tax acquired IPR&D and milestones expense, reducing both GAAP and adjusted diluted EPS by $0.41. Full-year 2026 adjusted EPS guidance falls to $13.96-$14.16 from the $14.37-$14.57 range given on February 4, 2026, and AbbVie says its guidance excludes any such expense incurred after the first quarter. Shareholders face a lower earnings outlook, and the quarter's results have not been finalized.
Key points
- Q1 2026 acquired IPR&D and milestones expense of $744 million pre-tax, an unfavorable $0.41 impact on GAAP and adjusted diluted EPS
- Full-year 2026 adjusted diluted EPS guidance now $13.96-$14.16, versus $14.37-$14.57 previously
- Q1 2026 adjusted diluted EPS guidance now $2.56-$2.60, versus $2.97-$3.01 before the charge
- Quarter ended March 31, 2026 results not finalized and may differ from these preliminary estimates
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.